Blueprint
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of June 2017
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X
Form
40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __ No
X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule
12g3-2(b): 82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
AZ agreement with
Grünenthal for rights to Zomig
7 June 2017
ASTRAZENECA ENTERS AGREEMENT WITH GRÜNENTHAL TO DIVEST RIGHTS
TO MIGRAINE TREATMENT ZOMIG
AstraZeneca
today announced that it has entered an agreement with
Grünenthal for the global rights to Zomig (zolmitriptan) outside
Japan. Zomig is indicated
for the acute treatment of
migraines and cluster headaches, an area of medicine outside AstraZeneca's
strategic focus.
Grünenthal
will pay AstraZeneca $200 million upon completion. AstraZeneca will
also receive up to an additional $102 million in future milestone
payments. Grünenthal will acquire the rights to Zomig in all markets outside Japan,
including the US, where the
rights were previously licensed to Impax Pharmaceuticals (Impax).
Impax will continue to market Zomig
in the US. AstraZeneca will
continue to manufacture and supply the medicine to
Grünenthal during a transition period.
Mark
Mallon, Executive Vice President, Global Product & Portfolio
Strategy at AstraZeneca said:
"Grünenthal is an established partner with expertise in
the treatment of pain. It is well placed to ensure patients
continue to benefit from Zomig, and to extend the commercial
potential of the medicine through its dedicated
salesforce."
Gabriel
Baertschi, CEO of Grünenthal said: "Migraine is a very
debilitating disease with more than 75 million people worldwide
suffering from attacks that can lead to sensitivity to light or
sound, to nausea or even vomiting. The acquisition of the
well-established Zomig
products complements our existing pain portfolio. Migraine has been
one of the very few main pain indications we haven't yet been able
to offer a solution for. This is an important step to reach our
ambition to become a €2 billion company by 2022. It will also
support our efforts to bring four to five innovative products to
market in the same timeframe."
Financial considerations
In
2016, revenues from Zomig
outside Japan were $96 million, including Product Sales and
Externalisation Revenue. The transaction is expected to
complete in the second quarter of 2017, subject to customary
closing conditions and regulatory clearances. The net consideration
from the agreement will be reported as Other Operating Income in
the Company's financial statements. The agreement does not
impact the Company's financial guidance for 2017.
About Zomig
Zomig (zolmitriptan)
is indicated for the acute treatment of migraine, and for the acute
treatment of cluster headache in the EU. Zomig is available in
three formulations: An oral tablet, orally dispersible tablet and
nasal spray.
About Grünenthal
The Grünenthal Group is an entrepreneurial, science-based
pharmaceutical company specialized in pain, gout and inflammation.
Our ambition is to deliver four to five new products to patients in
diseases with high unmet medical need by 2022 and become a €2
billion company. We are a fully integrated research &
development company with a long track record of bringing innovative
pain treatments and state-of-the-art technologies to patients. By
sustainably investing in our R&D above the industrial average,
we are strongly committed to innovation.
Grünenthal is an independent, family-owned company
headquartered in Aachen, Germany. We are present in 32 countries
with affiliates in Europe, Latin America and the US. Our products
are sold in more than 155 countries and approx. 5,500 employees are
working for the Grünenthal Group worldwide. In 2016,
Grünenthal achieved revenues of approx. €1.4 bn. More
information: www.grunenthal.com.
Follow us on LinkedIn:
@GrunenthalGroup
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that
focuses on the discovery, development and commercialisation of
prescription medicines, primarily for the treatment of diseases in
three main therapy areas - Oncology, Cardiovascular &
Metabolic Diseases and
Respiratory. The Company also is selectively active in the areas of
autoimmunity, neuroscience and infection. AstraZeneca operates in
over 100 countries and its innovative medicines are used by
millions of patients worldwide. For more information, please
visit www.astrazeneca.com and
follow us on Twitter @AstraZeneca.
Media
Enquiries
|
|
|
Esra
Erkal-Paler
|
UK/Global
|
+44 203
749 5638
|
Karen
Birmingham
|
UK/Global
|
+44 203
749 5634
|
Rob
Skelding
|
UK/Global
|
+44 203
749 5821
|
Jacob
Lund
|
Sweden
|
+46
8 553 260 20
|
Michele
Meixell
|
US
|
+1 302
885 2677
|
Investor
Relations
|
|
|
Thomas
Kudsk Larsen
|
|
+44 203
749 5712
|
Craig
Marks
|
Finance,
Fixed Income, M&A
|
+44
7881 615 764
|
Henry
Wheeler
|
Oncology
|
+44 203
749 5797
|
Mitchell
Chan
|
Oncology
|
+1 240
477 3771
|
Lindsey
Trickett
|
Cardiovascular
& Metabolic Diseases
|
+1 240
543 7970
|
Nick
Stone
|
Respiratory
|
+44 203
749 5716
|
Christer
Gruvris
|
Autoimmunity,
Neuroscience & Infection
|
+44 203
749 5711
|
US toll
free
|
|
+1 866
381 7277
|
Adrian Kemp
Company Secretary, AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
AstraZeneca
PLC
Date:
07 June 2017
|
By: /s/
Adrian Kemp
|
|
Name:
Adrian Kemp
|
|
Title:
Company Secretary
|